Clinical Trial Update: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection [Phase 2]

View source ↗

Summary

Phase 2 trial to evaluate safety and antiviral activity of JNJ-53718678 in children aged 28 days to 3 years with respiratory syncytial virus infection; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• JNJ-53718678

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: TERMINATED | Results posted: 2023-09-21